Ariel Precision Medicine

Executive Summary

Ariel Precision Medicine is a Pittsburgh-based biotechnology company founded in 2015 that leverages its proprietary ADVANCE AI platform to integrate genetic and clinical data for discovering and developing therapies for complex chronic diseases. The company's initial focus is on CFTR-related disorders beyond cystic fibrosis, targeting a broad range of conditions driven by CFTR dysfunction. By combining advanced computational biology with clinical insights, Ariel aims to identify novel drug targets and biomarkers, potentially enabling precision treatments for underserved patient populations. The company is privately held and has not disclosed funding rounds or valuation, but its technology platform differentiates it in the precision medicine space.

Upcoming Catalysts (preview)

• Q2 2027Lead Program IND Filing for CFTR Modulator30% success
• Q4 2026Partnership or Licensing Deal with Larger Pharma40% success
• Q1 2027Publication of ADVANCE Platform Validation Data70% success